triple agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-05 and is reviewed periodically as new material appears.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
=== Fatty acid oxidation disorders === With the advent of tandem mass spectrometry as a screening tool, several fatty acid oxidation disorders were targeted for inclusion in newborn screening programs. Medium chain acyl-CoA dehydrogenase deficiency (MCADD), which had been implicated in several cases of sudden infant death syndrome was one of the first conditions targeted for inclusion. MCADD was the first condition added when the United Kingdom expanded their screening program from PKU only. Population based studies in Germany, the United States and Australia put the combined incidence of fatty acid oxidation disorders at 1:9300 among Caucasians. The United States screens for all known fatty acid oxidation disorders, either as primary or secondary targets, while other countries screen for a subset of these. The introduction of screening for fatty acid oxidation disorders has been shown to have reduced morbidity and mortality associated with the conditions, particularly MCADD. An Australian study found a 74% reduction in episodes of severe metabolic decompensation or death among individuals identified by newborn screening as having MCADD versus those who presented clinically prior to screening. Studies in the Netherlands and United Kingdom found improvements in outcome at a reduced cost when infants were identified before presenting clinically. Newborn screening programs have also expanded the information base available about some rare conditions.
However, it continued to conduct its work independently. In September 2022, the Lancet commission published a wide-ranging report on the pandemic, including commentary on the virus origin overseen by the group's chairman, economist Jeffrey Sachs. The report suggested that the virus may have originated from an American laboratory, a notion promoted by Sachs since late 2020, including in 2022 on the podcast of anti-vaxx conspiracy theorist Robert F. Kennedy Jr. Reacting to the Commission report, virologist Angela Rasmussen commented that this may have been "one of The Lancet's most shameful moments regarding its role as a steward and leader in communicating crucial findings about science and medicine". Virologist David Robertson said the invocation of US laboratory involvement was "wild speculation" and that "it's really disappointing to see such a potentially influential report contributing to further misinformation on such an important topic". The task force published their own report in October 2022, saying they concluded there was "overwhelming" evidence of a natural spillover, but they also accepted the possibility of a lab leak.
==== 24 Hour Jungle Ration (no longer available) ==== The 24 Hour Jungle ration is based on the standard 24 Hour ration with additional supplements and a Flameless Ration Heater (FRH). The Jungle ration is designed for use by the special forces and other specialist units. The 24 Hour Jungle Ration provides a minimum of 4500 kcals (18,840 kJ) a day.
== Activities == In August 1987 Schabort attended and spoke at a commemorative service for Rudolf Hess organised by the Afrikaner Weerstandsbeweging (AWB). The BBB would organise inflammatory meeting and marches. The BBB sought to link with international right-wing organisations. The BBB ran a "blatantly racist" bilingual magazine Kommando: Stem van die Blankedom/Kommando: Voice of the White Race published by Alan Harvey. Harvey was deputy leader of the South Natal branch (its leader was Peter Smith); Harvey had previously published and edited the South African Patriot magazine in Durban, under the "Patriotic Press" imprint. This magazine carried advertisements of several far right organisations around the world, including David Duke's the National Association for the Advancement of White People, National Vanguard magazine issued by the National Alliance, Instauration magazine, the British cultural magazine Heritage and Destiny, the National Front's Nationalism Today (to which Harvey contributed both under his own name and under the pseudonym "John Humphries"), and NF News. Harvey contributed to the BBB's publication under his own name.
Sources: en.wikipedia.org
A weak and emaciated Tolkien spent the remainder of the war alternating between hospitals and garrison duties, being deemed medically unfit for general service. During his recovery in a cottage in Little Haywood, Staffordshire, he began to work on what he called The Book of Lost Tales, beginning with The Fall of Gondolin. Lost Tales represented Tolkien's attempt to create a mythology for England, a project he would abandon without ever completing. Throughout 1917 and 1918 his illness kept recurring, but he had recovered enough to do home service at various camps. It was at this time that Edith bore their first child, John Francis Reuel Tolkien. In a 1941 letter, Tolkien described his son John as "(conceived and carried during the starvation-year of 1917 and the great U-boat campaign) round about the Battle of Cambrai, when the end of the war seemed as far off as it does now". Tolkien was promoted to the temporary rank of lieutenant on 6 January 1918. When he was stationed at Kingston upon Hull, he and Edith went walking in the woods at nearby Roos, and Edith began to dance for him in a clearing among the flowering hemlock. After his wife's death in 1971, Tolkien remembered:
Rarely is Huntington's disease caused by a new mutation, where neither parent has over 36 CAG repeats. In the rare situations where both parents have an expanded HD gene, the risk increases to 75%, and when either parent has two expanded copies, the risk is 100%. Individuals with both genes affected are rare. For some time, HD was thought to be the only disease for which possession of a second mutated gene did not affect symptoms and progression, but it has since been found that it can affect the phenotype and the rate of progression.
In February 2022, Carrey reprised his role as Ernie "Chip" Douglas, from the 1996 movie The Cable Guy, in a commercial for Verizon, which aired during the Super Bowl. In April 2022, Carrey announced that he was considering retirement, saying: "I have enough. I've done enough. I am enough." He said he would return to acting if "angels bring some sort of script that's written in gold ink that says to me that it's going to be really important for people to see". In February 2024, it was announced that Carrey would reprise his role as Dr. Ivo Robotnik in Sonic the Hedgehog 3. A copy of the script for Sonic the Hedgehog 3 was delivered to Carrey written in 24-carat ink in reference to his previous comments. Carrey also plays Ivo Robotnik's grandfather, Gerald Robotnik. Carrey reportedly told an Associated Press reporter that he agreed to return to the Sonic universe because "I need the money, frankly." He later clarified in interviews in December 2024 that he planned to "power rest" rather than retire, while also stating that he was open to continuing his role in the Sonic film series. In March 2026, Carrey was announced to return as Dr. Ivo Robotnik in Sonic the Hedgehog 4 (2027). In August 2026, Carrey was announced to star in the upcoming live-action film The Jetsons, but his role is yet to be confirmed.
== Distribution and habitat == Sun anemones are marine organisms that are distributed in shallow areas of the sea floor, typically at depths from 1–10 m. This species is epibenthic. Commonly called the Caribbean Sun Anemone, S. helianthus are predominantly found in the Caribbean and Western Atlantic Seas. Additionally, they have been discovered along the coast of the United States, Canada, Costa Rica and Belize. S. helianthus may live singularly, but commonly live in dense aggregations such as in reef formations.
liposome Also cellule, spherule, or spherulite. 1. Any small, natural lipid globule, such as a micelle, occurring naturally in the cytoplasm; they are commonly formed by budding off from larger membrane-bound vesicles. 2. A small, spherical, artificial vesicle having at least one continuous bilayer of lipid molecules enclosing some of the medium in which it is suspended. Liposomes can be created in the laboratory by disrupting existing biological membranes and allowing complex lipids to form bilayer-bound vesicles in aqueous solution, usually with the aid of sonication. They are used experimentally as models of natural membranes and also therapeutically for the encapsulation and delivery of pharmaceutical compounds, enzymes, nutrients, nucleic acids, lipid-based nanoparticles (as in some vaccines), and many other agents between or inside of cells.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.